Skip to main content
. 2017 Jan;19(1):4–23. doi: 10.1016/j.jmoldx.2016.10.002

Table 3.

Categories of Clinical and/or Experimental Evidence

Category Therapeutic Diagnosis Prognosis
Level A 1. Biomarkers that predict response or resistance to FDA-approved therapies for a specific type of tumor
2. Biomarkers included in professional guidelines that predict response or resistance to therapies for a specific type of tumor
Biomarkers included in professional guidelines as diagnostic for a specific type of tumor Biomarkers included in professional guidelines as prognostic for a specific type of tumor
Level B Biomarkers that predict response or resistance to therapies for a specific type of tumor based on well-powered studies with consensus from experts in the field Biomarkers of diagnostic significance for a specific type of tumor based on well-powered studies with consensus from experts in the field Biomarkers of prognostic significance for a specific type of tumor based on well-powered studies with consensus from experts in the field
Level C 1. Biomarkers that predict response or resistance to therapies approved by the FDA or professional societies for a different type of tumor
2. Biomarkers that serve as inclusion criteria for clinical trials
Biomarkers of diagnostic significance based on the results of multiple small studies Biomarkers of prognostic significance based on the results of multiple small studies
Level D Biomarkers that show plausible therapeutic significance based on preclinical studies Biomarkers that may assist disease diagnosis themselves or along with other biomarkers based on small studies or a few case reports Biomarkers that may assist disease prognosis themselves or along with other biomarkers based on small studies or a few case reports

FDA, Food and Drug Administration.